Table 3.
Histopathological parameters and relative expression levels of galectin-1/3 mRNA in all patients with RCC
| Sample/pathology | n | Mean relative expression (ΔΔCt) | SD |
|---|---|---|---|
|
LGALS1 |
106 |
|
|
| Male |
68 |
1.58 |
0.87 |
| Female |
38 |
1.37 |
0.91 |
| Age (< median) |
54 |
1.50 |
0.96 |
| Age (≥ median) |
52 |
1.48 |
0.81 |
| M0 |
83 |
1.41 |
0.90 |
| M+ |
23 |
1.77 |
0.78 |
| N0 |
95 |
1.44 |
0.86 |
| N+ |
11 |
1.97 |
1.03 |
| Localized RCC* |
57 |
1.34 |
0.89 |
| Advanced RCC* |
49 |
1.67 |
0.86 |
| Grade (≤2) |
89 |
1.46 |
0.85 |
| Grade (> 2) |
17 |
1.63 |
1.09 |
|
LGALS3 |
105 |
|
|
| Male |
38 |
-0.41 |
1.04 |
| Female |
67 |
-0.06 |
0.79 |
| Age (< median) |
54 |
-0.25 |
0.97 |
| Age (≥ median) |
51 |
-0.12 |
0.82 |
| M0 |
82 |
-0.18 |
0.90 |
| M+ |
23 |
-0.23 |
0.92 |
| N0 |
94 |
-0.21 |
0.86 |
| N+ |
11 |
-0.001 |
1.23 |
| Localized RCC* |
56 |
-0.13 |
0.91 |
| Advanced RCC* |
49 |
-0.25 |
0.89 |
| Grade (≤ 2) |
88 |
-1.62 |
0.9 |
| Grade (> 2) | 17 | -0.43 | 0.91 |
SD = standard deviation, N+ = lymph node metastasis, M+ = organ metastasis. ∗Advanced RCC was defined as pT ≥3, N1 and/or M1, or G>2.